FEB 17, 2019 03:17 PM PST

Drug Combination May Become Standard Treatment for Metastatic Kidney Cancer

WRITTEN BY: Nouran Amin

Reporting from results of a phase 3 clinical trial, patients with metastatic kidney cancer may soon receive a new standard treatment involving a combination of two drugs. The drugs, axitinib plus the immunotherapeutic agent avelumab, were seen to significantly decrease tumor size better that the current treatment involving the drug sunitinib (Sutent), used specifically in the treatment of renal cell carcinoma.

Learn more about kidney cancers:

"Patients receiving the drug combination also had a higher response rate -- meaning their tumors shrank -- than the sunitinib-only group," says Toni K. Choueiri, MD, senior and co-corresponding author of the report and The Jerome and Nancy Kohlberg Professor of Medicine at Harvard Medical School. "This is certainly better than sunitinib -- hopefully this will lead to Food and Drug Administration approval soon.”

The drug combination, particularly involving the immunotherapeutic—avelumab, works by not only targeting the vascular endothelial growth factor receptor (VEGFR) to disrupt the blood supply to tumors but by also inhibiting and immune checkpoint called PD-L1 which naturally works to exhausts immune T cells—this will ensure the effective attack of cancer cells.

"Interestingly, the analysis showed that all subgroups -- good, intermediate, and poor-risk patient -- benefited from the combination treatment," said Choueiri. This was the topic of an oral presentation Choueiri has just given at the 2019 Genitourinary Cancers Symposium in San Francisco. The results were simultaneously published in the New England Journal of Medicine.

Almost all patients in the study experienced some form of side effects—with the most frequent being thyroid disorders in the drug combination group. However, Dr. Choueiri states that for patients with advanced stage of cancer, the drug combination will serve as "an important option. What we're doing in advanced kidney cancers is pushing the envelope -- these treatments may not be curative, but patients are living longer, and the disease is becoming more chronic."

Source: Dana-Farber Cancer Institute

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 20, 2019
Drug Discovery & Development
NOV 20, 2019
Does Modafinil Really Increase Brain Function?
Modafinil, often sold under the name “Provigil”, is a wakefulness-promoting drug used to treat excessive sleeping in conditions such as narcole...
NOV 20, 2019
Cancer
NOV 20, 2019
Cancer drugs don't work the way we thought
New research recently published in the journal Science Translational Medicine surprises the oncological community with findings that a protein previously t...
NOV 20, 2019
Drug Discovery & Development
NOV 20, 2019
Common Drug May Prevent Thousands Deaths from Head Injury
Each year, there are over 60 million new cases of traumatic brain injury (TBI). Mostly caused by road traffic crashes and falls, TBI often causes intracran...
NOV 20, 2019
Drug Discovery & Development
NOV 20, 2019
Fecal Transplants Could Treat Irritable Bowel Syndrome
According to the American College of Gastroenterology, between 10 and 15% of Americans have Irritable Bowel Syndrome (IBS). Although treatments are current...
NOV 20, 2019
Drug Discovery & Development
NOV 20, 2019
Possible New Drug Targets for Glioblastoma
Scientists at Karolinska Institutet in Sweden were able to pinpoint 10 tumor-specific potential drug targets for the fatal and incurable brain cancer, glio...
NOV 20, 2019
Neuroscience
NOV 20, 2019
Does New Chinese Alzheimer's Drug Made from Seaweed Work?
It has been almost two decades since the last drug for Alzheimer’s was approved. Now, Chinese reglators have granted conditinal approval for a new dr...
Loading Comments...